Bavarian Nordic A/S (CPH: BAVA)
Denmark
· Delayed Price · Currency is DKK | Market Cap | 15.12B |
| Revenue (ttm) | 6.07B |
| Net Income (ttm) | 1.12B |
| Shares Out | 78.54M |
| EPS (ttm) | 14.26 |
| PE Ratio | 13.50 |
| Forward PE | 8.30 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 336,388 |
| Open | 192.90 |
| Previous Close | 193.05 |
| Day's Range | 189.05 - 193.45 |
| 52-Week Range | 143.40 - 300.00 |
| Beta | 1.54 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 15, 2024 |
About Bavarian Nordic
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phas... [Read more]
Financial Performance
Financial StatementsNews
Bullish On Bavarian Nordic's Vaccine Portfolio And Revenue Potential In 2025
Bavarian Nordic's Mpox Moment Fades, But Diversification Shines
Bavarian Nordic's mpox vaccine sales have declined post-outbreak, causing reduced revenue and highlighting its reliance on outbreak-driven demand. The company's Travel Health segment demonstrated stre...
How one vaccine maker responded to a question about RFK Jr. as health secretary
Bavarian Nordic, a maker of the mpox vaccine, on Friday said the incoming Trump administration may present opportunities even after the announcement that noted vaccine skeptic Robert F. Kennedy Jr. ha...
Bavarian Nordic A/S (BVNKF) Q3 2024 Earnings Call Transcript
Bavarian Nordic A/S 2024 Q3 - Results - Earnings Call Presentation
The following slide deck was published by Bavarian Nordic A/S in conjunction with their 2024 Q3 earnings call.
Bavarian Nordic reports results for first nine months; reaffirms upgraded guidance for FY24
Bavarian Nordic CEO says Kennedy nomination could fuel vaccine scepticism
Danish biotech Bavarian Nordic anticipates a boost in biodefense funding by the incoming U.S. administration despite concerns that the nomination of Robert F. Kennedy Jr. as health secretary could fue...
Bavarian Nordic has $340 mln orders for its mpox, smallpox vaccine in 2025
Danish biotech Bavarian Nordic said on Friday the order book for delivery of its vaccine for mpox and smallpox in 2025 currently totals around 2.40 billion crowns ($340 million), including previously ...
Bavarian Nordic Announces Interim Results for the First Nine Months of 2024
COPENHAGEN, Denmark, November 15, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results for the first nine months of 2024 and business progress for the third quarter of ...
First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic's Mpox Vaccine
COPENHAGEN, Denmark, October 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a clinical study of the MVA-BN® mpox/smallpox vaccine in children 2 to 11 years of age.
WHO approves Bavarian Nordic's mpox vaccine for adolescents
The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the disea...
Bavarian Nordic in pact with UNICEF for 1M mpox shots
Bavarian Nordic (BVNRY) signs agreement with UNICEF to supply 1M doses of its mpox vaccine MVA-BN for African countries affected by the current outbreak. Read more here.
Bavarian Nordic signs agreement with UNICEF for one million mpox vaccines
Bavarian Nordic said on Thursday it has signed an agreement with the UNICEF for one million mpox vaccines, which include 500,000 doses that were committed by the Gavi vaccine alliance.
Bavarian Nordic Signs Agreement with UNICEF for 1 Million Mpox Vaccines
COPENHAGEN, Denmark, September 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced an agreement with UNICEF for the supply of 1 million doses of the MVA-BN® mpox vaccine for countries in Africa...
Bavarian Nordic Upgrades its Financial Guidance for 2024
COPENHAGEN, Denmark, September 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) upgrades its financial guidance for 2024.
Bavarian Nordic said to have won $63M mpox vaccine contract from U.S.
Bavarian Nordic (BVNRY) secures $63M U.S. government contract to manufacture components for Jynneos, its FDA approved vaccine for smallpox and mpox. Read more here.
Bavarian Nordic gets $63 million US government order for small pox, mpox vaccine
Bavarian Nordic has received an order worth $63 million from the U.S. government to produce additional bulk product and the final freeze-dried doses of its mpox and smallpox vaccine, Jynneos, it said ...
Bavarian Nordic Awarded USD 63 Million from the U.S. Government for Production and Supply of Additional Smallpox/Mpox Vaccines
COPENHAGEN, Denmark, September 24, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced that it has received an additional order valued at USD 63 million from the Biomedical Advanced Research and De...
Bavarian Nordic Receives EMA Approval of Mpox Vaccine for Adolescents
COPENHAGEN, Denmark, September 19, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that the European Commission has adopted the Committee for Medicinal Products for Human Use (CHMP) recommendat...
Bavarian Nordic in pact with global vaccine group, Gavi for 500K mpox vaccines
Bavarian Nordic's (BVNRY) agrees to supply 500,000 doses of its MVA-BN mpox vaccine to Africa as part of a deal with Gavi, the global vaccine alliance. Read more here.
Gavi to buy 500,000 mpox vaccine doses from Bavarian Nordic
The global vaccine group Gavi will buy 500,000 doses of Bavarian Nordic's mpox vaccine, its first purchase of the shot to help battle an outbreak in parts of Africa, the group said on Wednesday.
Gavi Signs Agreement with Bavarian Nordic to Rapidly Secure 500,000 Doses of Mpox Vaccines for Africa
COPENHAGEN, Denmark and GENEVA, Switzerland, September 18, 2024 – Bavarian Nordic A/S (OMX: BAVA) and Gavi, the Vaccine Alliance today announced an advance purchase agreement (APA) to secure 500,000 d...
UK Secures Additional Doses Of Bavarian Nordic Mpox Vaccine To Combat New Variant Threat
The U.K. government has secured over 150,000 doses of the mpox vaccine from Bavarian Nordic A/S (OTC: BVNRY) (OTC: BVNKF) to strengthen the nation's defenses against clade I mpox . The vaccines will...
UK government buys over 150,000 doses of Bavarian Nordic's mpox vaccine
The UK government has ordered more than 150,000 doses of Bavarian Nordic's mpox vaccine to boost its preparedness against a new form of the virus currently spreading in African countries.
First mpox vaccine approved by WHO in effort to combat disease in Africa
The World Health Organisation has granted its first authorisation for an mpox vaccine in adults, produced by Bavarian Nordic A/S. This marks a significant step in combating the disease, especially in ...